EMD Serono today became the 21st pharmaceutical manufacturer to impose conditions on 340B pricing involving drug shipments to contract pharmacies.
Bayer announced conditions on 340B sales involving contract pharmacies earlier today. The companies’ announcements came two days after the U.S. Third Circuit Court of Appeals ruled the 340B statute does not require drug makers to deliver discounted 340B drugs to an unlimited number of contract pharmacies. Federal appeals courts in Washington, D.C., and Chicago are expected to rule soon in similar cases.
EMD Serono today became the 21st pharmaceutical manufacturer to impose conditions on 340B pricing involving drug shipments to contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
